CA-VISA
21.12.2021 12:02:09 CET | Business Wire | Press release
Visa (NYSE:V) today announced it has further expanded its support of women’s football by becoming the first Women’s Football Partner for the FIFA Women’s World Cup 2023™. This investment builds on long-term commitments Visa has made across Europe and around the world, to help elevate women’s football and usher in greater equality within the sport.
“Women are a force to be reckoned with – on the pitch, as small business owners, and as drivers of a majority of consumer purchases. We know that when we support the success of women in sport, we support the success of women everywhere,” said Lynne Biggar, Chief Marketing Officer, Visa. “Becoming the first FIFA Women’s Football Partner is part of a much larger investment in women’s initiatives to help recognize the limitless potential of women around the world.”
Visa is one of the world’s most active sponsors of women’s football. Through the company’s sponsorship of the FIFA Women's World Cup 2023™ and other leading women’s football organizations around the world, the company strives to be a catalyst for change and contribute to the growing recognition of women’s football. The FIFA Women's World Cup 2019™ tournament was watched by a record 1.12 billion viewers1 and marked Visa’s largest onsite investment in women’s football, providing the latest payment technology at all venues and curating exclusive experiences for consumers and clients from around the world.
As the FIFA Women’s World Cup™ heads to Australia and New Zealand in 2023, marking the first time the Tournament will be played across two countries and be expanded to 32 teams, Visa will enable similar one-of-a-kind experiences for football fans globally, activate the Player of the Match award and incorporate its Team Visa program for women footballers. Additionally, as the Exclusive Payment Service for the FIFA Women’s World Cup 2023™, Visa will implement its innovative payment technology at tournament venues and deliver exclusive experiences for fans and clients, ranging from delivering innovative ways to pay to utilizing Visa’s exclusive marketing campaign assets to drive mutual business priorities with clients.
“As a long-standing FIFA Partner and a proud supporter of women’s football, it was a natural choice for Visa to become the first ever Women’s Football Partner at FIFA,” said Sarai Bareman, FIFA’s Chief Women’s Football Officer. “Visa is well known for supporting athletes and seeing the positive benefits that can come through sport. They are advocates for equality, diversity, and inclusion, core values that are shared by FIFA and the FIFA Women’s World Cup, as we grow and celebrate the women’s game.”
Given the correlation between success in sport and business – 94% of women in the C-suite have played a sport at some time in their lives2 – Visa’s support for women does not end on the pitch. Visa continues to develop programs that open more opportunities for women on and off the field:
- Team Visa: Designed to help athletes succeed in their athletic career and beyond, Team Visa has championed more than 500 athletes since its inception. Of those athletes, 55% are women, including 22 female footballers such as Lucy Bronze (England), Alexia Putellas (Spain) and Ellie Carpenter (Australia).
- The Second Half: Launched in the UK in early 2021, the Second Half is a Visa career development program to support female footballers as they consider careers beyond football. The program helps women recognize how to translate the skills they have developed – perseverance, teamwork, and commitment – outside of sport.
- She’s Next, Empowered by Visa: Broader Visa programs – such as She’s Next – support women entrepreneurs around the world and work to close gaps with educational tools, mentorship and meaningful funding.
“I love having the opportunity to encourage young people to chase their dreams and am so proud to be part of Team Visa because the company shares this same vision and supports what I do,” said Ellie Carpenter, defender on Australia’s national women’s football team. “To be looking ahead toward playing the FIFA Women’s World Cup 2023™ in my home country is an absolute dream come true.”
Visa’s first-ever sponsorship of the FIFA Women’s World Cup 2023™ complements its global investment in women’s football , including its ground-breaking partnership with UEFA Women’s Football, and sponsorship of the U.S. Soccer Federation, including the U.S. Women’s National Team and the SheBelieves Cup. It also builds on Visa’s longstanding partnership with FIFA, including the FIFA World Cup™, FIFA Women's World Cup™ and other FIFA events.
About Visa Inc.
Visa (NYSE: V) is a world leader in digital payments, facilitating more than 215 billion payments transactions between consumers, merchants, financial institutions and government entities across more than 200 countries and territories each year. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com
.
____________________
1
FIFA
, October 2019
2
EY, “Why a Female Athlete Should Be Your Next Leader”
, September 2020
View source version on businesswire.com: https://www.businesswire.com/news/home/20211221005151/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom